We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with ...

Aromatase inhibitors (AIs) are a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male hormones) into estrogens (female hormones). These medications ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

"What's important is that these drugs significantly reduce late recurrences," says Isaacs. But she notes that researchers still don't know which strategy works best: taking an aromatase inhibitor ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Do innovator drugs work better than generic ... Ask the Pharmacists, November 2010 Can the Duration of Aromatase Inhibitor Therapy Exceed 5 Years? Does extended-duration aromatase inhibitor ...

when the SMC gave the green light for restricted prescribing of the drug in first-line HR+/HER2- breast cancer in combination with aromatase inhibitor drugs. Both are also trying to get the okay ...

One of the most common drugs used for hormonal therapy for breast cancer is Tamoxifen. A new group of hormonal therapies called aromatase inhibitors may also be an option.

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Treatment with the aromatase inhibitor anastrozole decreased the ... (New York Times) Disparities in access to novel anti-obesity drugs could be made worse if the medications are denied to people ...